Cytomorphological patterns of thyroid lesions among 1646 Sudanese patients: what we can learn from fine needle aspiration cytology retrospective analysis? [version 1; peer review: 1 approved with reservations]

Ali I. E. Osman¹, Ahmed O. Almobarak², Asma Kamalaldin Mohammed¹, Nouh S. Mohamed³-⁵, Mohamed S. Muneer⁶,⁷, Ammar B. Omer⁸, Hussam M. A. Ibrahim⁸, Emmanuel E. Siddig⁹-¹¹, Eman T. Ali¹,¹², Abdalla Munir¹³, Ali M. M. Edris¹,¹⁴, Eiman S. Ahmed⁹, Lubna S. Elnour¹², Rowa Hassan¹⁹,¹⁵

¹Department of Histopathology and Cytology, University of Khartoum, Sudan, Khartoum, 11115, Sudan  
²Faculty of Medicine, University of Medical Sciences and Technology, Khartoum, 11115, Sudan  
³Department of Parasitology and Medical Entomology, Nile University, Khartoum, 11115, Sudan  
⁴Department of Parasitology and Medical Entomology, Faculty of Medicine, Sinnar University, Sinnar, Sudan  
⁵Department of Molecular Biology, National University Biomedical Research Institute, National University, Khartoum, Sudan  
⁶Department of Neurology, Mayo Clinic, Jacksonville, FL, USA  
⁷Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan  
⁸International University of Africa, Khartoum, Sudan  
⁹Mycetoma Research Center, University of Khartoum, Khartoum, Sudan  
¹⁰School of Medicine, Nile University, Khartoum, Sudan  
¹¹Alfarabi College for Science and Technology, Khartoum, Sudan  
¹²Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, 11115, Sudan  
¹³Department of Bioinformatics and Biostatistics, National University, Khartoum, 11115, Sudan  
¹⁴Department of Histopathology and Cytology, Faculty of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia  
¹⁵Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, BN1 9PX, UK

Abstract

Introduction: Fine-needle aspiration (FNA) cytology biopsy of the thyroid gland is an accurate and useful diagnostic tool in the initial evaluation of nodular thyroid lesions. We aimed in this study to determine the cytomorphological patterns of thyroid lesions diagnosed by FNA among Sudanese patients.

Methods: A descriptive retrospective, clinic-based study was performed. Cytopathological records of patients that attended the Total Lab Care Clinic in Khartoum-Sudan between January 2016 and December 2017 were reviewed.

Results: A total of 1646 patients records were reviewed; 1385 (84.1%) were females and 261 (15.9%) males. A total of 1563 (94.9%) were negative for malignancy, 39 (2.4%) were positive for malignancy, 42 (2.6%) were indeterminate for malignancy and 2 (0.1%) were non-diagnostic.
Colloid goiter was seen in 1147 patients (73.4%), benign hemorrhagic cysts were seen in 257, Hashimoto thyroiditis was seen in 77, benign thyroid nodules were seen in 76, keratocysts were seen in 2, thyroglossal duct cysts were seen in 2, thyroid follicular adenoma was seen in 1 and myxedema was seen in 1. For malignant patients; 11 had anaplastic thyroid cancer, 8 had papillary thyroid cancer, 7 had follicular thyroid cancer, 5 had metastatic thyroid cancer, 4 had medullary thyroid cancer, 3 had non-Hodgkin lymphoma and 1 had thyroid follicular adenoma. For those indeterminate for malignancy, 24 had follicular neoplasm and 18 had Hurthle cell neoplasm.

**Conclusions:** Fine needle aspiration cytology for thyroid nodules provides a rapid and non-invasive technique for the evaluation and differentiation between benign and malignant lesions. This study also addresses the increased predominance of benign thyroid lesions among young patients and thyroid malignancy among the 4th decade of life.

**Keywords**
Thyroid nodules, Cytomorphological features, Fine Needle Aspiration, Sudan.

**Corresponding author:** Emmanuel E. Siddig (emanwell-eds3@hotmail.com)

**Author roles:**
- **Osman AIE:** Formal Analysis, Investigation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Almobarak AO:** Conceptualization, Data Curation, Investigation, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Mohammed AK:** Writing – Original Draft Preparation;
- **Mohamed NS:** Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Muneer MS:** Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Omer AB:** Writing – Original Draft Preparation, Writing – Review & Editing;
- **Siddig EE:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Ali ET:** Conceptualization, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Edris AMM:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Ahmed ES:** Conceptualization, Investigation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Elnour LS:** Writing – Original Draft Preparation, Writing – Review & Editing;
- **Hassan R:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing;

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2020 Osman AIE et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Osman AIE, Almobarak AO, Mohammed AK et al. Cytomorphological patterns of thyroid lesions among 1646 Sudanese patients: what we can learn from fine needle aspiration cytology retrospective analysis? [version 1; peer review: 1 approved with reservations] F1000Research 2020, 9:23 (https://doi.org/10.12688/f1000research.21492.1)

**First published:** 16 Jan 2020, 9:23 (https://doi.org/10.12688/f1000research.21492.1)
**Introduction**

Fine-needle aspiration cytology (FNA) biopsy of the thyroid gland is an accurate and useful diagnostic tool in the initial evaluation of the nodular thyroid lesions. Since ≤5% of thyroid nodules are malignant, most thyroid swellings are non-neoplastic and may not require surgical intercession. Although surgical management of thyroid nodules is a feasible option, it is associated with many adverse effects, including development of hypoparathyroidism and an enduring need for thyroid hormone replacement therapy, and also risk during surgical intercession such as injury of the recurrent nerves, bacterial infections of the surgery wound, and other related factors. Therefore, to avoid unnecessary thyroid surgery, the standardized Bethesda scoring system and the ACR Thyroid Imaging Reporting and Data System (ACR TI-RADS) have been developed to empower clinicians to perform suitable therapeutic intercessions. When an accurate preoperative diagnosis can be made, and no subsequent risk of malignant changes was suspected, surgery can be avoided. FNA is one of the initial preoperative screening procedures for the diagnosis of nodular thyroid disease and considered as the most accurate diagnostic modality, with a sensitivity ranging between 43 to 95%, and specificity of 47 to 100% for thyroid lesions. This wide range of sensitivity and specificity is attributed to the testing of suspicious and rare cases and the inclusion of occult papillary carcinoma in the category of false negative diagnosis. Also, FNA is a safe and useful procedure for the differential diagnosis of thyroid malignancies, such as medullary thyroid carcinoma.

In Sudan, ultrasound-guided FNA is considered to be an expensive technique in order to be either provided by the hospital or requested by the physician managing the patient. Lacking the epidemiological data addressing the prevalence of thyroid malignancy in Sudan, besides, there is no recent descriptive study updating the status of thyroid malignancy through the past six years. Therefore, this study aimed at determining the cytomorphological patterns of thyroid lesions diagnosed by FNA among Sudanese patients attending a cytology clinic in Khartoum state, Sudan from January 2016 to December 2017.

**Methods**

**Patients and setting**

A descriptive retrospective, clinic-based study in which we reviewed records of all patients referred to the Thyroid Nodule Center at the Total Lab Care Clinic in Khartoum state, Sudan for the evaluation of nodular thyroid disease from January 2016 to December 2017. Other than the presence of thyroid disease, no other eligibility criteria were used. The retrospective data, including type of disease, macroscopic appearance and malignancy status, were collected from the cytopathological records and sorted synonymously for analysis.

**FNA and diagnosis**

FNA was performed previously by two expert physicians using the palpation technique. In cases of multinodular lesions and complex nodules consisting of solid and fluid matters, FNA was done multiple times to avoid sampling from single nodule or aspirating cystic fluid only. Uninodular lesions with solid composition were aspirated four times to avoid bias due to sampling from single area and to insure coverage of the whole nodule. Meanwhile, in case of small nodules which were difficult to palpate (<1 cm), cystic nodules and/or nodules located posteriorly in the thyroid gland, ultrasound guided FNA were done by experienced radiologist using a LOGIQ P5 Trackball device (Guangzhou Rongtai Medical Technology Co., Ltd, China). Four smears for each patient were taken from different regions of the thyroid nodule in order to prevent misdiagnosis. The four FNA smears of each patient were fixed in 95% ethanol according to procedures outlines by Safneck et al. Then, two smears were stained using Papanicolaou (Pap) stain and the other two were stained using May–Grunwald Giemsa (MGG) stain, as described previously. Cytopathologic diagnosis was performed by two experienced cytopathologists using microscopy with a high-power magnification lenses (X40). Both cytopathologists’ results were compared with each other to confirm the diagnosis. Results of diagnosis of smears were categorized as non-diagnostic if insufficient cellular material was present and no evidence of cellular atypia was found (<6 groups of cells containing ≥15 cells each), and into negative for malignancy, positive for malignancy and indeterminate for malignancy according to the Bethesda System for Reporting Thyroid Cytopathology.

A total of 1646 patients were identified and their smears were reviewed. The main cytomorphological features used for classification of thyroid nodules used included; cellularity of smears, cellular architectures (microfollicles and macrofollicles), cohesiveness, nuclear to cytoplasmatic ratio, intactness of cell membrane, size of nuclei, pleomorphism, shape of nuclei, condensation of chromatin, alteration of nuclear contours, prominence of conspicuous nucleoli, and presence of pseudo-inclusions, nuclear grooves, and nuclear enlargement. Additionally, the presence or absence of Hurthle cells, amyloid, colloid, psammoma bodies, inflammatory cells, necrotic material, and tumor diathesis. The criteria of the Bethesda System for Reporting Thyroid Cytopathology were followed.

**Statistical analysis**

Descriptive data were analyzed using the Statistical Package for the Social Sciences (SPSSv16). Pearson Chi Square Test was used to test the relationship between the different categorical variables. P value < 0.05 was considered a statistically significant.

**Ethical approval**

Ethical approval was obtained from the ethics committee of the Faculty of Medical Laboratory Science, University of Khartoum-Sudan (UoK, FMLS 01/2017). Written informed consent for the procedure and for use of patient data for publication were obtained previously by the Thyroid Nodule Center at the Total Lab Care Clinic.

**Results**

The study population consisted of 1385 (84.1%) females with mean age of 42.46±14.19, and 261 (15.9%) males with mean age of 48.29±16.84. The male to female ratio was 1:5.3. Age of patients...
was grouped based on interval of 10 years, age group with peak thyroid lesions was 31 to 40 years followed by 41 to 50 years.

Based on the Bethesda system, results of both cytopathologists were compared with each other to obtain the final diagnosis. Each smear was diagnosed by the first cytopathologist was matching to the diagnosis of the second cytopathologist. The retrospective results of the cytomorphological features of the FNA and data recorded about the size of swellings, site of swelling distributed based on age group were shown in Table 1. Size of swelling was significantly associated with malignancy (P=0.006), whereas site of swelling was not. Individual results for each patient are available as Underlying data.

### Patient history of thyroideotomy and family history of thyroid disease

In total, 13/1646 patients only reported past medical history of thyroideotomy of one thyroid lobe, while the remaining 1633/1646 were not having any previous surgical removal of any of the thyroid lobes.

Family history of thyroid diseases were only reported among the negative and positive for malignancy, 77/1646 and 39/1646 respectively. Having family history of thyroid diseases was statistically significant (p = 0.0001).

Family history with thyroid diseases among patients diagnosed with malignancies was mostly noted among anaplastic carcinoma 11/39, followed by papillary thyroid cancer and follicular thyroid cancer (8/39 and 7/39, respectively). However, the remaining malignancies were also reported: 5/39 patients with metastatic cancer, 4/39 with medullary thyroid cancer and 3/39 patients with non-Hodgkin lymphoma.

Patients positive for malignancy were classified as follows: 11 (28.2%) had anaplastic thyroid cancer, 8 (20.5%) papillary thyroid cancer, 7 (17.9%) follicular thyroid cancer, 5 (12.8%) metastatic thyroid cancer, 4 (10.2%) medullary thyroid cancer, 3 (7.8%) non-Hodgkin lymphoma and 1 (2.6%) patient with thyroid follicular adenoma presenting malignant cells. Patients aged 61–70 years showed higher frequency of malignancy (Table 2).

In patients indeterminate for malignancy, the most frequent ages were 21 to 50 years, the peak age group was between the 20–39 years. The FNA diagnosis of the indeterminate for thyroid malignancy were grouped into two diagnostic verdicts, 24 (57.1%) as follicular neoplasm and 18 (43.9%) as Hurthle cell neoplasm. Figure 1 shows the different cytomorphological patterns of the thyroid lesions diagnosed in this study.

### Table 1. Distribution of gender, site and size of swelling based on age group.

<table>
<thead>
<tr>
<th>Age groups of patients</th>
<th>1–10 years</th>
<th>11–20 years</th>
<th>21–30 years</th>
<th>31–40 years</th>
<th>41–50 years</th>
<th>51–60 years</th>
<th>61–70 years</th>
<th>71–80 years</th>
<th>81–90 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2 (0.8%)</td>
<td>13 (5.0%)</td>
<td>27 (10.3%)</td>
<td>43 (16.5%)</td>
<td>28 (14.0%)</td>
<td>33 (16.5%)</td>
<td>31 (14.0%)</td>
<td>27 (17.9%)</td>
<td>42 (22.9%)</td>
<td>261 (15.9%)</td>
</tr>
<tr>
<td>Female</td>
<td>2 (0.1%)</td>
<td>61 (4.4%)</td>
<td>248 (17.9%)</td>
<td>387 (27.9%)</td>
<td>320 (23.1%)</td>
<td>204 (14.7%)</td>
<td>121 (8.7%)</td>
<td>38 (2.7%)</td>
<td>4 (0.3%)</td>
<td>1385 (84.1%)</td>
</tr>
<tr>
<td><strong>Site of Swelling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>4 (0.3%)</td>
<td>61 (5.0%)</td>
<td>217 (17.8%)</td>
<td>317 (26.0%)</td>
<td>291 (23.9%)</td>
<td>173 (14.2%)</td>
<td>111 (9.1%)</td>
<td>41 (3.4%)</td>
<td>3 (0.2%)</td>
<td>1218 (74.0%)</td>
</tr>
<tr>
<td>Left</td>
<td>0 (0.0%)</td>
<td>2 (1.4%)</td>
<td>12 (26.7%)</td>
<td>7 (15.6%)</td>
<td>6 (13.3%)</td>
<td>5 (11.1%)</td>
<td>1 (2.2%)</td>
<td>0 (0.0%)</td>
<td>45 (2.7%)</td>
<td></td>
</tr>
<tr>
<td>Central</td>
<td>0 (0.0%)</td>
<td>11 (2.9%)</td>
<td>46 (12.0%)</td>
<td>101 (26.4%)</td>
<td>79 (20.6%)</td>
<td>77 (20.1%)</td>
<td>47 (12.3%)</td>
<td>18 (4.7%)</td>
<td>4 (1.0%)</td>
<td>383 (23.3%)</td>
</tr>
<tr>
<td><strong>Size of Swelling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2.9 cm</td>
<td>3 (1.1%)</td>
<td>20 (7.2%)</td>
<td>59 (21.4%)</td>
<td>79 (28.6%)</td>
<td>44 (15.9%)</td>
<td>42 (15.2%)</td>
<td>21 (7.6%)</td>
<td>7 (2.5%)</td>
<td>1 (0.4%)</td>
<td>276 (16.8%)</td>
</tr>
<tr>
<td>3-5.9 cm</td>
<td>1 (0.1%)</td>
<td>44 (4.2%)</td>
<td>183 (17.5%)</td>
<td>272 (26.1%)</td>
<td>264 (25.3%)</td>
<td>143 (13.7%)</td>
<td>98 (9.4%)</td>
<td>35 (3.4%)</td>
<td>3 (0.3%)</td>
<td>1043 (63.4%)</td>
</tr>
<tr>
<td>6-9.9 cm</td>
<td>0 (0.0%)</td>
<td>7 (2.6%)</td>
<td>28 (10.5%)</td>
<td>68 (25.5%)</td>
<td>59 (22.1%)</td>
<td>56 (21.0%)</td>
<td>33 (12.4%)</td>
<td>13 (4.9%)</td>
<td>3 (1.1%)</td>
<td>267 (16.2%)</td>
</tr>
<tr>
<td>≥ 10 cm</td>
<td>0 (0.0%)</td>
<td>3 (5.0%)</td>
<td>5 (8.3%)</td>
<td>11 (18.3%)</td>
<td>10 (16.7%)</td>
<td>15 (25.0%)</td>
<td>11 (18.3%)</td>
<td>5 (8.3%)</td>
<td>0 (0.0%)</td>
<td>60 (3.6%)</td>
</tr>
<tr>
<td><strong>FNA diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-diagnostic</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (100%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (0.1%)</td>
</tr>
<tr>
<td>Negative for malignancy</td>
<td>4 (0.3%)</td>
<td>73 (4.7%)</td>
<td>264 (16.9%)</td>
<td>416 (26.6%)</td>
<td>360 (23.0%)</td>
<td>239 (15.3%)</td>
<td>149 (9.5%)</td>
<td>53 (3.4%)</td>
<td>5 (0.3%)</td>
<td>1563 (94.9%)</td>
</tr>
<tr>
<td>Indeterminate for malignancy</td>
<td>0 (0.0%)</td>
<td>1 (2.4%)</td>
<td>8 (19.0%)</td>
<td>10 (23.9%)</td>
<td>8 (19.0%)</td>
<td>6 (14.3%)</td>
<td>4 (9.5%)</td>
<td>4 (9.5%)</td>
<td>1 (2.4%)</td>
<td>42 (2.6%)</td>
</tr>
<tr>
<td>Positive for malignancy</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>3 (7.7%)</td>
<td>4 (10.3%)</td>
<td>9 (23.1%)</td>
<td>9 (23.1%)</td>
<td>10 (25.5%)</td>
<td>3 (7.7%)</td>
<td>1 (2.6%)</td>
<td>39 (2.4%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>4 (0.2%)</td>
<td>74 (4.5%)</td>
<td>275 (16.7%)</td>
<td>430 (26.1%)</td>
<td>377 (22.9%)</td>
<td>256 (15.6%)</td>
<td>163 (9.9%)</td>
<td>60 (3.6%)</td>
<td>7 (0.4%)</td>
<td>1646 (100%)</td>
</tr>
</tbody>
</table>
Table 2. Distribution of fine needle aspiration diagnosis across the different Bethesda system categories based on age group.

<table>
<thead>
<tr>
<th>Age groups of patients</th>
<th>1–10 years</th>
<th>11–20 years</th>
<th>21–30 years</th>
<th>31–40 years</th>
<th>41–50 years</th>
<th>51–60 years</th>
<th>61–70 years</th>
<th>71–80 years</th>
<th>81–90 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-diagnostic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infected cyst</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (100%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (0.1%)</td>
<td></td>
</tr>
<tr>
<td>Negative for malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenomatous goiter</td>
<td>0 (0.0%)</td>
<td>2 (14.3%)</td>
<td>5 (35.7%)</td>
<td>3 (21.4%)</td>
<td>3 (21.4%)</td>
<td>1 (7.1%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>14 (0.9%)</td>
</tr>
<tr>
<td>Benign thyroid nodule</td>
<td>1 (1.3%)</td>
<td>4 (5.3%)</td>
<td>14 (18.4%)</td>
<td>25 (32.9%)</td>
<td>12 (15.8%)</td>
<td>6 (7.9%)</td>
<td>2 (2.6%)</td>
<td>0 (0.0%)</td>
<td>76 (4.6%)</td>
<td></td>
</tr>
<tr>
<td>Colloid goiter</td>
<td>1 (0.1%)</td>
<td>56 (4.9%)</td>
<td>186 (16.4%)</td>
<td>300 (26.5%)</td>
<td>258 (22.8%)</td>
<td>180 (15.9%)</td>
<td>112 (9.9%)</td>
<td>35 (3.1%)</td>
<td>5 (0.4%)</td>
<td>1133 (68.8%)</td>
</tr>
<tr>
<td>Hashimoto's thyroiditis</td>
<td>0 (0.0%)</td>
<td>4 (5.2%)</td>
<td>16 (20.6%)</td>
<td>21 (27.3%)</td>
<td>18 (23.4%)</td>
<td>9 (11.7%)</td>
<td>6 (7.8%)</td>
<td>3 (3.9%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic cyst</td>
<td>1 (0.4%)</td>
<td>7 (2.7%)</td>
<td>41 (16.0%)</td>
<td>67 (26.1%)</td>
<td>69 (26.8%)</td>
<td>36 (14.0%)</td>
<td>25 (9.7%)</td>
<td>11 (4.3%)</td>
<td>0 (0.0%)</td>
<td>257 (15.6%)</td>
</tr>
<tr>
<td>Keratocyst</td>
<td>1 (50.0%)</td>
<td>0 (0.0%)</td>
<td>1 (50.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (0.1%)</td>
</tr>
<tr>
<td>Myxedema</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Thyroglossal duct cyst</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (50.0%)</td>
<td>0 (0.0%)</td>
<td>1 (50.0%)</td>
<td>0 (0.0%)</td>
<td>2 (0.1%)</td>
</tr>
<tr>
<td>Thyroid follicular adenoma</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Indeterminate for malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follicular neoplasm</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>3 (12.5%)</td>
<td>6 (25.0%)</td>
<td>4 (16.7%)</td>
<td>4 (16.7%)</td>
<td>2 (8.3%)</td>
<td>4 (16.7%)</td>
<td>1 (4.2%)</td>
<td>24 (1.5%)</td>
</tr>
<tr>
<td>Hurthle cell neoplasm</td>
<td>0 (0.0%)</td>
<td>1 (5.6%)</td>
<td>5 (27.8%)</td>
<td>4 (22.2%)</td>
<td>4 (22.2%)</td>
<td>2 (11.1%)</td>
<td>2 (11.1%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>18 (1.1%)</td>
</tr>
<tr>
<td>Positive for malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaplastic thyroid cancer</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>2 (18.2%)</td>
<td>2 (18.2%)</td>
<td>1 (9.1%)</td>
<td>5 (45.5%)</td>
<td>1 (9.1%)</td>
<td>0 (0.0%)</td>
<td>11 (0.7%)</td>
</tr>
<tr>
<td>Follicular thyroid cancer</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (14.3%)</td>
<td>1 (14.3%)</td>
<td>0 (0.0%)</td>
<td>2 (28.6%)</td>
<td>1 (14.3%)</td>
<td>1 (14.3%)</td>
<td>1 (14.3%)</td>
<td>7 (0.4%)</td>
</tr>
<tr>
<td>Medullary thyroid cancer</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (25.0%)</td>
<td>0 (0.0%)</td>
<td>1 (25.0%)</td>
<td>0 (0.0%)</td>
<td>2 (50.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>4 (0.2%)</td>
</tr>
<tr>
<td>Papillary thyroid cancer</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (12.5%)</td>
<td>1 (12.5%)</td>
<td>4 (50.0%)</td>
<td>1 (12.5%)</td>
<td>1 (12.5%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>8 (0.5%)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (33.3%)</td>
<td>2 (66.7%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>3 (0.2%)</td>
</tr>
<tr>
<td>Metastatic thyroid cancer</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (20.0%)</td>
<td>2 (40.0%)</td>
<td>1 (20.0%)</td>
<td>1 (20.0%)</td>
<td>0 (0.0%)</td>
<td>5 (0.3%)</td>
</tr>
<tr>
<td>Thyroid follicular adenoma</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Total</td>
<td>4 (0.2%)</td>
<td>74 (4.5%)</td>
<td>275 (16.7%)</td>
<td>430 (26.1%)</td>
<td>377 (22.9%)</td>
<td>256 (15.6%)</td>
<td>163 (9.9%)</td>
<td>60 (3.6%)</td>
<td>7 (0.4%)</td>
<td>1646 (100%)</td>
</tr>
</tbody>
</table>

Discussion

Thyroid nodules are a common clinical problem. FNA of the thyroid is practiced worldwide and is reliable and cost-effective diagnostic procedure to diagnose thyroid lesions that may need surgical excision or conservative management. The key factors to ensure informative thyroid FNA are having an adequate or representative cell sample and expertise of the healthcare professional performing the thyroid cytology.

Thyroid cancer is the most common endocrine cancer (approximately 1.0%–1.5% of all new cancers diagnosed each year) and its incidence has continuously increased in the last three decades all over the world, including Sudan. In this study, thyroid cancers were seen predominantly among those aged 30–59 years with the peak age in those aged 50–59 years. These results are in agreement with previous reports. In this study, most of the diagnosed thyroid lesions were found to be benign in...
nature. However, in another study conducted by Caruso and his colleagues, they reported a lower percentage (74%) of benign thyroid lesions in more than 9000 patients; Gharib et al., after reviewing 11,000 specimens, found 69% of examined thyroid lesions were benign lesions. Although benign nodules were reported to display morphologic changes over time, these were referred to as degenerative or mummified nodules. This observation can lead to a non-diagnostic result on FNA, which could increase the incidence of unnecessary thyroid surgery. Remarkably, the higher rate of colloid goiter among the benign lesions detected in this study can be related to the following reasons as discussed in the literature: iodine deficiency, overgrowth of normal thyroid tissue, thyroid cyst, chronic inflammation of the thyroid (thyroiditis), multinodular goiter, thyroid cancer. In the current study, the relatively higher frequency of the colloid goiter from all retrieved thyroid lesions was in parity with previous reports conducted in Sudan. Also, these results were in concordance with Nadira et al., which shows that colloid goiter represent about 77.2% of the thyroid lesions. Additionally, Hadi et al. revealed quite similar results of colloid goiter in 66.6% of the total cases.

Regarding thyroiditis, Hashimoto thyroiditis had the highest prevalence. Hashimoto thyroiditis is a common autoimmune disease characterized by marked lymphoid infiltrate destroying the thyroid follicles; it has a peak incidence between 40 and 60 years of age and a female predominance. In the present study, Hashimoto thyroiditis were common among patients falling in the age between 21 and 50 years. But, Bhatia and his colleagues observed the commonest age group is those 20–39 years of age. Also, female predominance has been
observed in this study which agrees with previous published studies.\textsuperscript{46,50–52}

With respect to malignant thyroid lesions, nearly 3\% of the study cases were diagnosed as malignant and the majority of these were in females. Moreover, the malignant cases were reported to be in those between 30 and 59 years of age. Although anaplastic carcinoma occurs in approximately 2\% of reported thyroid cancer cases,\textsuperscript{53} this study depicted that anaplastic carcinoma accounted the highest proportion of thyroid malignancies followed by papillary thyroid carcinoma and follicular thyroid carcinoma in Sudan. This result is comparatively different from other studies showed higher prevalence of thyroid malignancy.\textsuperscript{34,54}

Our study has highlighted several potential benefits of FNA which is consistent with the previous studies addressing the FNA reimbursements.\textsuperscript{33,55,56} The most important benefits are that FNA is a simple, safe and cost-effective first-line method to investigate thyroid lesions, particularly in low-resource settings such as Sudan, in which most of the patients suffering from thyroid lesions presented late to the clinics due to their low-income status. Furthermore, the diagnosis of benign lesions is 50-fold that of malignant ones; this can be interpreted as an increase in the community awareness about thyroid diseases as well as more clinicians recognizing the utility of FNA in evaluating thyroid nodules\textsuperscript{57–59}. However, further studies considering this increase in benign lesions showed be well investigated in respect to all factors associated with developing benign thyroid lesions.

Limitations
Most of the patients underwent surgical removal in different clinics. Therefore, follow-up data of the negative for malignancy lesions that showed non-neoplastic features were not correlated with the clinical presentation and ultrasonographic findings to conclude the final diagnosis. Follow up data of the repeated palpation, FNA and ultrasound at 6–18 months intervals to detect the appearance of significant growth or suspicious sonographic changes were not feasible to obtain from all the study participants and were excluded to avoid bias.

Conclusions
This study showed the usefulness of FNA in the evaluation of thyroid lesions and a high diagnostic performance for detection and differentiation of benign lesions from malignancy, with low rates of technical failures and complications with respect to patients’ economic status since ultrasound guided FNA were only used for palpable nodules. Also, this study addresses the increased predominance of benign thyroid lesions among young patients and thyroid malignancy among those aged 30–39.

Data availability
Harvard Dataverse: Cytomorphological Patterns of Thyroid Lesions among 1646 Sudanese Patients: What can we learn from Fine Needle Aspiration Cytology Retrospective Analysis? https://doi.org/10.7910/DVN/AYEZVP (version 2)\textsuperscript{60}.

This project contains the following underlying data:

- Thyroid data (underlying data, including demographic details and information about malignancy, in SAV format).
- Thyroid research (2) (underlying data in XLSX format).

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgements
We are of great thanks for kind collaboration and assistance of the clinical staff of Thyroid Nodule Clinic at the Total Lab Care Clinic, Khartoum, Sudan during slide examination and interpretations. Great thanks to all participants contributed to this work.

References

The article describes the results of large number of thyroid FNA in Sudan where similar studies are scarce. Therefore, this study is useful to give us insight about that area. However, it's not clear to me how the FNA categories were made. The authors talk in the beginning about the use of Bethesda system; which is a 6-tier system (unsatisfactory, benign, atypia of uncertain significance, follicular/Hurthle cell lesions, suspicious and malignant). Then, authors divide their results into 4-tiers only excluding both atypical categories (AUS and susp.). Does that mean they always have a definite diagnosis in cytology? Or these are final results correlating with other parameters in these cases?

It is also a well known face that cytology can not discriminate in follicular or Hurthle cell lesions between adenoma and carcinoma. Yet in this article, we see some cases labelled as adenoma or carcinoma, while others are labelled as neoplasm. It's not clear how that distinguishing was made. Is it based on availability of histology in some cases? Or other criteria e.g. lymph node metastasis by radiology?

It's also slightly unusual as authors stated that anaplastic carcinoma carcinoma is the most common type in the malignant category. Are there any possible causes? E.g. population selection or criteria used?

As authors stated lack of follow-up data or surgical excision data for negative cases is a limitation of this study. However, it was not clear if they have any excision data in other categories. If this data is available, I think that will add to the strength of the study and its reflection of the usefulness of thyroid FNA in making diagnosis.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Anatomic and cellular pathology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com